Stockwatch: Teva And Mylan Hit Terminal Velocity
Executive Summary
Another social media jump on the drug pricing bandwagon by Hillary Clinton directed at Mylan's EpiPen pricing policy temporarily sank most life science stock prices last week. Fortunately, the lasting impact should be limited to Teva and Mylan.
You may also be interested in...
PTAB Knocks Out Two Copaxone 40 mg Patents
Patent Trial and Appeal Board finds claims in '250 and '413 patents covering 40 mg dosage are unpatentable, giving generic manufacturers a chance at early entry once FDA approves ANDAs.
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan's $600 price tag for its emergency anaphylaxis treatment EpiPen (epinephrine) could spur more than probes into the company's pricing practices. It could turn into a wider investigation into industry's use of patient assistance programs.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.